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Targeting Cellular Calcium 
Homeostasis to Prevent Cytokine-
Mediated Beta Cell Death
Amy L. Clark1, Kohsuke Kanekura2, Zeno Lavagnino3, Larry D. Spears4, Damien Abreu4,  
Jana Mahadevan4, Takuya Yagi4, Clay F. Semenkovich3,4, David W. Piston3 & Fumihiko Urano4,5
Pro-inflammatory cytokines are important mediators of islet inflammation, leading to beta cell death 
in type 1 diabetes. Although alterations in both endoplasmic reticulum (ER) and cytosolic free calcium 
levels are known to play a role in cytokine-mediated beta cell death, there are currently no treatments 
targeting cellular calcium homeostasis to combat type 1 diabetes. Here we show that modulation of 
cellular calcium homeostasis can mitigate cytokine- and ER stress-mediated beta cell death. The calcium 
modulating compounds, dantrolene and sitagliptin, both prevent cytokine and ER stress-induced 
activation of the pro-apoptotic calcium-dependent enzyme, calpain, and partly suppress beta cell 
death in INS1E cells and human primary islets. These agents are also able to restore cytokine-mediated 
suppression of functional ER calcium release. In addition, sitagliptin preserves function of the ER calcium 
pump, sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), and decreases levels of the pro-apoptotic 
protein thioredoxin-interacting protein (TXNIP). Supporting the role of TXNIP in cytokine-mediated cell 
death, knock down of TXNIP in INS1-E cells prevents cytokine-mediated beta cell death. Our findings 
demonstrate that modulation of dynamic cellular calcium homeostasis and TXNIP suppression present 
viable pharmacologic targets to prevent cytokine-mediated beta cell loss in diabetes.
Type 1 diabetes mellitus (T1DM) results from an autoimmune attack on insulin producing beta cells that leads to 
immune cell infiltration of the pancreatic islets, inflammation, and beta cell death. Several studies have employed 
immunosuppression to prevent T1DM, but this modality alone does not alter the course of T1DM in humans1–4. 
This is likely secondary to the fact that there are some intrinsic features in the propagation of islet inflammation 
and beta cell death in T1DM that persist despite immunosuppression. Our goal is to target beta cell specific 
molecular pathways involved in initiation of autoimmunity and progression of cytokine-mediated beta cell death, 
which may identify novel therapies for beta cell preservation in T1DM. ER stress has been implicated in develop-
ment of autoimmunity, propagation of insulitis and beta cell death in T1DM5–13. As ER stress can potentially be 
involved in diabetes from development of autoimmunity to beta cell death, it is an attractive target for preventing 
beta cell death in T1DM.
Cytokines are potent inducers of ER stress and are known to promote autoimmune destruction of islets in 
T1DM10, 13–17. Cytokine stress leads to generalized ER dysfunction and altered cellular calcium homeostasis prior 
to initiating cell death. Specifically, cytokine exposure leads to pathogenic alterations in intracellular free calcium 
levels, including ER calcium depletion and cytosolic calcium elevation in beta cells10, 18–20. In addition to coordi-
nating protein synthesis and folding, the ER is involved in calcium storage and signaling, and is the source of both 
pro and anti-apoptotic signaling pathways21, 22. A high level of ER calcium is required for proper ER function in 
the context of protein folding and participation in cell signaling cascades. We have recently shown that ER calcium 
depletion, followed by a subsequent increase in cytoplasmic calcium, is seen in beta cells treated with inflamma-
tory cytokines20. Thus, targeting ER and cellular calcium homeostasis may prevent cytokine-mediated beta cell 
death in T1DM. Here we report that two well-characterized small molecules, dantrolene and sitagliptin, preserve 
functional ER calcium release in beta cells treated with inflammatory cytokines and suppress beta cell death.
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Results
To determine if modulation of ER and cytoplasmic free calcium levels can protect beta cells from 
cytokine-mediated cell death, we pretreated rat INS1-E cells with well-characterized Food and Drug 
Administration approved agents known to modulate cellular calcium levels. Drugs known to target cytosolic 
calcium levels included verapamil and sitagliptin. Drugs known to target ER calcium levels included pioglita-
zone and dantrolene16, 23–25. To determine if there would be any additive effect by altering both ER and cyto-
solic calcium levels, drugs were studied individually as well as in combination with one another. Cells were then 
challenged with a cytokine cocktail or the ER stress inducing agent thapsigargin. As expected, cytokines and 
thapsigargin significantly increased cell death as indicated by increased caspase 3/7 activity levels (Fig. 1a and b). 
In both cytokine and thapsigargin treated cells, dantrolene and sitagliptin significantly decreased beta cell death 
(Fig. 1a and b).
As dantrolene and sitagliptin provided significant protection against cytokine and ER stress-induced beta 
cell apoptosis, further studies were done to determine effects on ER stress, intracellular calcium levels and 
pro-apoptotic signals. Dantrolene and sitagliptin did not prevent cytokine-induced expression of the canonical 
ER stress markers CHOP or BiP26, 27 (Fig. 1c and d). However, sitagliptin did significantly lower expression of the 
pro-apoptotic thioredoxin-interacting protein (TXNIP) (Fig. 1e).
To determine if dantrolene and sitagliptin had significant effects on cytokine-induced ER calcium depletion, 
separate studies were done to monitor both baseline ER calcium levels as well as functional ER calcium release. 
To monitor baseline ER calcium levels, we created an INS-1E cell line stably expressing the ER-localized calcium 
sensor D1ER20, 28. Experiments in INS-1E-D1ER cells show that dantrolene and the combination of dantrolene 
and sitagliptin significantly increased ER calcium levels at baseline (Fig. 2a). However, despite increasing ER 
calcium at baseline, the drugs were not able to protect INS-1E cells from cytokine or thapsigargin-induced ER 
calcium depletion (Fig. 2a).
In order to examine drug effects on ER’s function to release calcium, caffeine-stimulated ER calcium release 
was monitored over time using confocal microscopy. Caffeine has been used previously to induce ER calcium 
release via activation of ryanodine receptors17, 29. The administration of caffeine, overall, resulted in increased 
frequency and magnitude of cytosolic calcium oscillations, as shown by the representative traces (Fig. 2b). This 
effect of caffeine can be seen for several minutes in healthy beta cells. Thus, monitoring caffeine-mediated calcium 
oscillations gives an indirect measure of the dynamic activity of the ER over time. To monitor ER calcium release, 
INS-1E cells loaded with the calcium indicator dye Fluo-4 were pre-treated with vehicle, dantrolene or sitagliptin, 
and exposed to a cytokine cocktail. The drugs were washed out prior to imaging, and Fluo-4 signal was imaged in 
Figure 1. Dantrolene and Sitagliptin Protect INS-1E Cells From Cytokine and ER Stress Induced Cell Death. 
(a,b) INS-1E cells were pre-treated with 100 nM dantrolene, 10 μM pioglitazone, 10 μM verapamil, or 200 nM 
sitagliptin for 24 hours then stressed for 24 hours with cytokine cocktail (IL-1β and IFN-γ 50 ng/mL) or 
thapsigargin 10 nM. Apoptotic cell death was measured via caspase 3/7 activity assay. (c–e) The ER stress markers 
CHOP BiP and TXNIP were measured using quantitative RT-PCR. Data are expressed as mean ± SEM from at 
least three independent experiments. #p < 0.05 compared to cytokine or TG treated cells via unpaired t-test.
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Figure 2. Dantrolene and Sitagliptin Restore Caffeine Mediated ER Calcium Release in Cytokine and ER 
Stressed Βeta Cells. (a) INS-1E cells were treated with 100 nM dantrolene, 200 nM sitagliptin or a combination 
of the two drugs for 24 hours followed by treatment with 10 nM thapsigargin for 24 hours or 6–24 hours of 
cytokine cocktail (IL-1β and IFN-γ 50 ng/mL) treatment. ER calcium levels were monitored in INS-1E cells 
stably expressing the D1ER probe via FACS analysis and presented as FRET/CFP. Fluorescence was monitored 
continuously for two minutes in INS-1E cells loaded with Fluo-4 AM imaged at baseline and after 5 mM 
caffeine stimulation and single cell calcium oscillation tracings were produced as depicted in panel b. Panel c 
shows representative single plane images at different times during the 2 minute acquisition after the addition 
of caffeine. Graphical representation of the relative change in fluorescence intensity averaged over 2 minutes of 
image acquisition, expressed as ΔF/F0 (ΔF is the change in fluorescence intensity of the caffeine stimulated cells 
relative to the basal condition F0) is displayed in the presence (panel d) and absence of calcium in the media 
(panel e). The average represents values over 2 minutes in 50 cells normalized for variations in the concentration 
of the dye in different cells. Data are expressed as mean ± SEM from at least three independent experiments. 
*p < 0.05 compared to control; #p < 0.05 compared to cytokine or TG treated cells via one way ANOVA test.
www.nature.com/scientificreports/
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the cells at baseline and after stimulation with caffeine. The value ΔF/F0 represents the change of Fluo-4 fluores-
cence when caffeine is added to the cells (ΔF) normalized to its initial signal (F0) as measured and averaged over 
a 2 minute period. As expected, control cells exhibited a robust increase in Fluo-4 signal upon caffeine exposure 
(Fig. 2c and d). Treatment with cytokines prevented ER calcium release so that there was no relative change 
in Fluo-4 intensity upon caffeine stimulation (Fig. 2c and d). In contrast, dantrolene and sitagliptin treatment 
resulted in a significant restoration of caffeine-mediated calcium release in cytokine treated cells. Experiments 
performed in calcium free buffer resulted in similar findings (Fig. 2e), which indicate that extracelluar calcium 
is not affecting these results. Taken together, the data suggest that while baseline ER calcium levles remained 
depleted dantrolene and sitagliptin were able to restore functional ER calcium release in cytokine-stressed beta 
cells.
The expression of the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) calcium transporter has been 
shown to be decreased by cytokine treatment10. Thus, we sought to determine if the drugs’ effect on functional 
ER calcium release was related to modulation of levels of SERCA. Immunoblotting and real-time PCR analysis 
did not indicate that dantrolene or sitagliptin effected SERCA2b mRNA or protein levels of SERCA in INS-1E 
cells at baseline (Fig. 3a and b). In addition neither drug had a significant effect on SERCA levels after cytokine 
stress (Fig. 3a and b). Next, we looked at SERCA activity during cytokine stress. SERCA activity was significantly 
decreased with cytokine treatment and restored by sitagliptin treatment (Fig. 3c). Collectively, these results sug-
gest sitagliptin does not increase SERCA levels but does lead to preservation of SERCA activity during cytokine 
stress.
We next used Fura-2 AM to study the effect of dantrolene and sitagliptin on cytokine and ER stress-induced 
elevation of cytosolic calcium. After 6 hours of exposure to cytokine cocktail, dantrolene and sitagliptin signifi-
cantly decreased cytosolic calcium levels compared to cells treated with cytokines alone. However, at 24 hours of 
cytokine treatment when cytosolic free calcium levels were significantly elevated, only dantrolene significantly 
lowered cytosolic free calcium levels (Fig. 4a). After 48 hours this effect was lost and neither drug effected cyto-
solic free calcium levels after thapsigargin treatment (Fig. 4a). These results suggest that the drugs have no signif-
icant effect on cytokine-mediated cytosolic calcium elevation.
To further determine the effects of dantrolene and sitagliptin on downstream calcium mediated cell death 
pathways, we assessed calpain activation. Calpain is a calcium-dependent enzyme whose hyperactivation has 
been shown to contribute to cell death in various diseases30, 31. To measure calpain activity we measured lev-
els of cleaved spectrin, an established calpain cleavage substrate32. Both dantrolene and sitagliptin significantly 
decreased cleaved spectrin levels in response to thapsigargin and cytokine stress (Fig. 4b and c). It has been pre-
viously shown that calpain-2 is involved in ER stress-mediated cell death33, 34. Thus, we further studied the role of 
calpain-2 in cytokine-mediated beta cell death using siRNA directed against calpain-2 along with the calpain-1 
and calpain-2 inhibiting compound calpain inhibitor III in INS-1E cells. We found that neither siRNA knock-
down of calapin-2 nor calpain inhibition suppressed cytokine-mediated cell death in INS-1E cells, suggesting that 
inactivation of calpain-1 or calpain-2 alone is not sufficient to prevent cytokine and ER stress-mediated beta cell 
death (Fig. 4d,e and f).
TXNIP is up-regulated by ER stress and ER calcium depletion and plays a critical role in beta cell death in cell 
and mouse models of T1DM35–37. Our data show that TXNIP mRNA levels are lower in sitagliptin treated cells 
stressed with cytokines (Fig. 1e). This raised the possibility that sitagliptin prevents cytokine mediated beta cell 
death by preventing TXNIP up-regulation. To test this idea, we established inducible TXNIP-knockdown INS1 
cells and challenged these cells with inflammatory cytokines (Fig. 5a)36. As predicted, suppression of TXNIP 
protected INS1 cells from cytokine-mediated beta cell death (Fig. 5b and c). These results provide compelling 
evidence that TXNIP may be a key regulator of cytokine mediated beta cell death. In addition, suppression of 
TXNIP levels may be a major mechanism by which sitagliptin protects against cytokine mediated beta cell death.
As cellular calcium signaling is key for glucose-stimulated insulin secretion (GSIS), we next set out to deter-
mine if the compounds had any effect on GSIS. The effect of dantrolene and sitagliptin on GSIS was examined in 
INS-1E cells as well as human islets (Fig. 6a and b). Results indicated that treatment with dantrolene and sitag-
liptin do not affect GSIS.
To determine if the effects seen in a rodent cell line are translatable to humans, we next pre-treated human pri-
mary islets from seven different donors with dantrolene or sitagliptin prior to cytokine or thapsigargin treatment 
and monitored cell death (Fig. 7a–h). While certain islet batches showed that the drugs had a protective effect 
(Fig. 7b,c), overall the drugs did not have a statistically significant effect on cytokine- or thapsigargin-mediated 
caspase 3/7 activation (Fig. 7a).
Discussion
In this study, we show that dantrolene and sitagliptin improve cytokine and ER stress-induced disruption of 
functional ER calcium release, partly prevent activation of the calcium-dependent protease calpain, and mitigate 
cytokine- and ER stress-mediated apoptosis in INS-1E cells. In addition, we have shown that TXNIP is a key 
mediator of cytokine-induced beta cell death. These results support stabilization of cellular calcium levels and 
TXNIP suppression as viable targets to protect against cytokine-mediated beta cell death in T1DM (Fig. 8).
The results of our human islet studies did not show a significant protection against cell death. While there is 
no in vitro system that perfectly mimics the pathophysiologic events in T1DM, human islets are often used to 
establish the translatability of a therapy. However, the fragility of primary human islets in culture along with the 
genetic and environmental heterogeneity of the donors often confound the translatability of human islet studies. 
Further studies utilizing various doses of dantrolene and sitagliptin may have yielded different results. However, 
due to the limited availablity of islets, this initial study focused on a single drug dose that showed effect in the first 
two donors. In additon, another commonly used model of T1DM, the Non-Obese Diabetic (NOD) mouse, may 
yield more results into the translatability of the drug effects into an in vivo model.
www.nature.com/scientificreports/
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Although both dantrolene and sitagliptin partly decreased cytokine-mediated beta cell death in INS-1 E cells, 
we could not see complete protection of these cells from cytokine-mediated cell death. This is probably due to 
the fact that cytokine induces beta cell death through multiple mechanisms including ER calcium-depletion and 
oxidative stress20, 38, 39. Combination therapy of anti-oxidant and dantrolene or sitagliptin could be a viable option 
for suppressing cytokine-mediated beta cell death.
There are multiple potential therapeutic avenues to increase ER calcium levels. Increased levels of SERCA2b 
are protective against cytokines and ER stress-induced ER calcium depletion and beta cell death16, 17, 20, 23. Thus, 
targeting drugs that increase SERCA levels may be one way to prevent beta cell death in T1DM. Blockade of 
ER calcium release via the ryanodine and IP3 receptors may also prevent cytokine-mediated beta cell death. 
Ryanodine receptors are present in the ER membrane and are the major source of ER calcium efflux40. Blockade 
of the ryanodine receptor by the drug dantrolene has previously been shown to decrease ER stress-induced ER 
calcium depletion and beta cell death, and in the current study prevents cytokine-mediated beta cell death25. 
One concern with blocking ER calcium release is that insulin secretion is calcium dependent. However, previous 
Figure 3. Sitagliptin Maintains SERCA Activity During Cytokine Stress. INS-1E cells were pre-treated with 
100 nM dantrolene or 200 nM sitagliptin for 24 hours then stressed for 24 hours with cytokine cocktail (IL-1β 
and IFN-γ 50 ng/mL). (a) SERCA protein levels were measured by immunoblot. Full-length blot can be seen 
on-line (Supplementary Figure 1). (b) SERCA2b mRNA levels were measured by real-time PCR. (c) SERCA 
activity levels were monitored and expressed as nmol Ca/min/mg protein. Data are expressed as mean ± SEM 
from at least three independent experiments. *p < 0.05 compared to control; #p < 0.05 compared to cytokine or 
TG treated cells via one way ANOVA test.
www.nature.com/scientificreports/
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work suggests that ryanodine receptor blockade does not negatively affect insulin release41. In addition, we have 
shown that dantrolene and sitagliptin have no effect on glucose stimulated insulin secretion in INS-1E cells and 
human islets. Thus, this study provides evidence that the blockade of the ryanodine receptors with drugs such as 
dantrolene or other novel compounds can decrease cytokine mediated beta cell death and may present a novel 
treatment for diabetes.
Pharmacologic modulation of cytosolic free calcium levels presents another pathway to prevent 
cytokine-induced beta cell death. Many beta cell stressors, including cytokines, hyperglycemia, and ER stress 
increase cytosolic free calcium levels20. Extreme or prolonged elevation of cytosolic free calcium induces activa-
tion of proteins and signaling cascades that result in beta cell death such as calpain42. Calpain hyper-activation has 
been shown to contribute to cell death in various diseases including diabetes30, 31. Beta cells have several isoforms 
of calpain and isoform 1,2 and 10 have specifically been associated with type 2 diabetes. However, no specific iso-
form has not been identified in association with T1DM43–45. This study demonstrates that inflammatory cytokines 
and ER stress induce calpain activation in INS-1E cells, which can be significantly diminished by treatment with 
dantrolene and sitagliptin. However, we also showed that suppression of calpain 1 and 2 activation alone is not 
sufficient to protect from cytokine mediated beta cell death. These data suggest that dantrolene and sitagliptin are 
likely affecting multiple pathways in addition to calpain activation to prevent cell death.
In this study we also identified that TXNIP expression was suppressed by sitagliptin. TXNIP is a pro-apoptotic 
component of the ER stress response and has been shown to be a critical link between ER stress and inflammas-
ome activation35, 36. Verapamil and other calcium lowering agents have been shown to decrease levels of TXNIP37. 
Prior studies have also shown that verapamil can prevent hyperglycemia, obesity and low dose streptozotocin 
(STZ) related beta cell death37. Our study shows that sitagliptin decreases expression of TXNIP and that TXNIP 
suppression can completely prevent cytokine mediated caspase 3/7 activation. This suggests TXNIP may be a 
potent target to prevent beta cell death in T1DM.
Figure 4. Dantrolene and Sitagliptin Significantly Decrease Calpain Activation in INS-1E Cells. (a) INS-1E 
cells were pre-treated with 100 nM dantrolene or 200 nM sitagliptin for 24 hours then stressed for 6–48 hours 
with cytokine cocktail (IL-1β and IFN-γ 50 ng/mL) or 10 nM thapsigargin. (a) cytosolic free calcium activity 
was determined in INS-1E cells via Fura-2 assay and presented as A340/A380. (b) Calpain activation was 
measured via immunoblot for spectrin cleavage products and (c) quantitative densitometry was performed 
via ImageJ software (NIH). Full-length blot can be seen on-line (Supplementary Figure 1). (d) INS-1E cells 
were transfected with SiRNA against a scrambled construct (SiSC) or calpain 2 (SiCAPN2) and immunoblot 
was performed for calpain-2 expression. (e) SiSC and SiCAPN2 transfected INS-1E cells were then exposed 
to cytokines (IL-1β and IFN-γ 50 ng/mL) or 10 nM thapsigargin for 24 hours and cell death was measured via 
caspase 3/7 activity. (f) INS-1E cellspre-treated for 24 hours with varying doses of calpain inhibitor III. Cells 
werethen stressed with cytokines (IL-1β and IFN-γ 50 ng/mL) or 10 nM thapsigargin for 24 hours and cell death 
was monitored via caspase 3/7 activity. Data are expressed asmean ± SEM from at least three independent 
experiments. #p < 0.05 compared tocytokine or TG treated cells unpaired t-test. Full-length blot can be seen on-
line (Supplementary Figure 1).
www.nature.com/scientificreports/
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Taken together, our studies support the hypothesis that drugs targeting stabilization of cellular calcium levels 
and suppression of TXNIP during pro-inflammatory cytokine stress can prevent beta cell death, thus establish-
ing modulation of ER and cytosolic free calcium levels and TXNIP suppression as viable options to prevent 
cytokine-mediated beta cell loss in diabetes.
Methods
Reagents. Thapsigargin, pioglitazone, dantrolene, verapamil and calpain inhibitor III were purchased from 
Sigma. Sitagliptin was purchased from Biovision Inc. Anti-GAPDH, anti-CHOP, anti-calpain 2 and anti-tubu-
lin antibodies were purchased from Cell Signaling. Anti-fodrin antibody for cleaved spectrin measurements 
was purchased from Enzo Life Sciences. Anti-SERCA antibody was purchased from Santa Cruz Biotechnology. 
Anti-TXNIP antibody was purchased from MBL International. 1:1000 dilution was used for immunoblot. Rat 
and human IL1-β and IFN-γ were purchased from R&D systems. Fluo-4 AM was purchased from Invitrogen/
Life Technologies. SiRNA directed against CAPN2 and control scramble siRNA were obtained from Origene 
Technologies.
Cell culture. INS-1E cells were a kind gift of Prof. Pierre Maechler, University of Geneva and not cotaminated 
with mycoplasma. INS-1E cells were cultured in RPMI-1640 medium supplemented with 10% FBS, antibiotics, 
sodium pyruvate, glutamax, non-essential amino acids, HEPES, and β-mercaptoethanol. Human Embryonic kid-
ney (HEK)-293 cells used in lentiviral production were cultured in DMEM containing 10% FBS and antibiotics. 
To establish INS-1E cell lines stably expressing the D1ER calcium probe, cells were transduced with lentivi-
rus expressing D1ER and selected by cell sorting via FACS. The calcium-sensing D1ER plasmid was generously 
gifted from Dr. Amy Palmer (University of Colorado, Boulder, Colorado) and subcloned into a lentiviral plasmid. 
SiRNA transfections were performed using TransIT (Mirus Bio LLC) per the manufacturer’s protocol.
Human Islet Studies. De-identified human islet preparations were acquired from PRODO labs or the 
Integrated Islet Distribution Program (IIDP). Informed consent was obtained from all subjects. Experiments 
were approved by Washington University’s Human Research Protection Office and conducted in accordance with 
the National Institutes of Health guidelines. Islets were allowed to recover overnight prior to experiments and 
were cultured in CMRL medium supplemented with FBS and penicillin/streptomycin. Islets were dispersed with 
0.05% trypsin EDTA and then plated to a 96 well plate for experiments.
Figure 5. Knock down of TXNIP in INS-1E Cells Prevents Cytokine Induced Caspase 3/7 Activity. (a) Western 
blot showing that TXNIP expression is decreased in tet-shTXNIP cells. Fold over control data are pooled from 
5 experiments. Full-length blot can be seen on-line (Supplementary Figure 1). (b) Stable Tet-shTXNIP INS1 cell 
lines were treated with DMSO or doxycycline for 48 hours followed by exposure to a cytokine cocktail of either 
10 ng/mL (panel b) or 50 ng/mL (panel c) IL-1β and IFN-γ for 24 hours. Caspase 3/7 activity was measured and 
data was presented as fold over control for each condition. Statistical analysis was done via two-tailed t tests 
#P < 0.05, n = 3–8.
www.nature.com/scientificreports/
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Measurement of ER calcium levels. INS-1E cells expressing D1ER cameleon were plated onto 6-well 
plates, treated with each compound for the indicated times, and then harvested by trypsinization. After washing 
with PBS, cells were resuspended in the Hanks’ buffered salt solution. Flow cytometry analyses were performed 
with LSRII (BD) at the FACS core facility of Washington University School of Medicine. The results were analyzed 
by FlowJo version 7.6.3 (Tree Star).
Measurement of apoptosis. INS-1E cells were plated to 96 well plates and were pre-treated with drugs 
or drug combinations for 24 hours. After pre-treatment, cytokine cocktail (IL1-β 50 ng/mL, IFN-y 50 ng/mL) 
or thapsigargin 10 nM was added to the cells for 24 hours. Caspase 3/7 activity was then detected using the 
Caspase-Glo® 3/7 Assay (Promega) using the Infinite M1000 plate reader (Tecan).
Quantitative real-time PCR. Total RNA was extracted using RNeasy kits (QIAGEN). RTPCR was per-
formed using ImPromII (Promega) reverse transcriptase, and quantitative PCR was performed using the 
Thermoscientific ViiA 7 real-time PCR system using SYBR green dye (Life Technologies). Primers were obtained 
from Integrated DNA Technologies (IDT) and sequences were as follows (sense and anti-sense); rat β-actin 
5′-GCA AAT GCT TCT ACG CGG AC-3′ and 5′-AAG AAA GGG TGT AAA ACG CAG C-3′, Rat BIP 5′-TGG 
GTA CAT TTG ATC TGA CTG GA-3′ and 5′-CTC AAA GGT GAC TTC AAT CTG GG-3′, Rat CHOP 5′-CTC 
ATT CTC CTG CTC CTT CTC C-3′ and 5′-AGA GTG GTC AGT GCG CAG C-3′, Rat SERCA2b 5′-TTT GTG 
GCC CGA AAC TAC CT-3′ and 5′-GGC ATA ATG AGC AGC ACA AAG GG-3′.
Measurement of SERCA Activity. The SERCA activity assay was performed as previously described46. 
INS-1E cells were lysed in a hypotonic buffer consisting of 10 mM NaHCO3, 250 mM sucrose, 5 mM NaN3, and 
1 mM PMSF. ER fractions were enriched using differential centrifugation. 50–75 μg of ER protein fractions were 
added to the assay mixture 100 mM KCL, 30 mM imidazole-histidine (pH 6.8), 5 mM MgCl2, 5 mM ATP, 5 mM 
(COOK)2, 5 mM NaN3 and 50 μM CaCl2 (10 μCi/μmol [45Ca]; CaCl2 American Radiolabled Chemicals) which 
was heated to 37 degrees for 15 minutes. The reaction was stopped by the addition of 250 mM KCl and 1 mM 
LaCl3. The mix was then vacuum filtered through a 0.2 um HT Tuffryn membrane (Pall). SERCA-dependent 
calcium transport was measured by using the SERCA inhibitor, 10 μM thapsigargin.
Figure 6. Dantrolene and Sitagliptin do not effect glucose stimulated insulin secretion (GSIS) in INS-1E cells or 
human islets. (a) INS-1E cells were treated with 100 nM dantrolene or 200 nM sitagliptin for 24 hours and GSIS 
assay was performed. Results are expressed as ng insulin secreted normalized for total protein. (b) Human islets 
from 3 separate donors were treated for 24 hours with 10 μM dantrolene or 200 nM sitagliptin and GSIS assay 
was performed. Results are expressed as ρg insulin secreted normalized to total DNA. Data are expressed as 
mean ± SEM. Statistical analysis to determine if drugs had an effect on insulin secretion was done via one-way 
ANOVA, n = 3–4.
www.nature.com/scientificreports/
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Figure 7. The Effect of Dantrolene and Sitagliptin on Cytokine Mediated Cell Death In Human Islets. (a–h) 
Human islet cells from 7 different organ donors were pre-treated for 24 hours with dantrolene 10 μM or 
sitagliptin 200 nM then stressed with cytokines (IL-1β 50 u/mL and IFN-γ 1000 u/mL) or thapsigargin 2 μM 
for 48 hours. Data are presented as combined results (panel a) as well as individual results (panel b–h) for all 
donors. Detailed information obtained from islet distribution centers on patient age, body mass index (BMI), 
hemoglobin A1C (A1C), Glucose Stimulated Insulin Release Stimulation Index (SI) and cause of death are 
presented in panel i. Data are expressed as mean ± SEM for all figures. #p < 0.05 compared to cytokine or TG 
treated cells unpaired t-test.
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Measurement of cytosolic free calcium activity. Cytosolic free calcium activity was assayed in INS-1E 
cells pre-treated for 24 hours with dantrolene 100 nM, sitagliptin 200 nM or drug combination followed by expo-
sure to cytokine cocktail (IL1-β 50 ng/mL, IFN-y 50 ng/mL), or thapsigargin 10 nM. Cytosolic free calcium activ-
ity was measured via the Fura-2 No Wash Calcium Assay (Abcam) per the manufacture’s protocol. Briefly, cells 
were plated in 96-well plates and stained with Fura-2 AM per manufacturers protocol. Fluorescence was meas-
ured at excitation wavelengths at 340 nm and 380 nm and emission wavelength at 510 nm. Then background was 
subtracted for both excitation wavelengths and the resulting values were used to calculate 340/380 ratios.
Measurement of caffeine stimulated calcium release. Confocal microscopy experiments were per-
formed on a Zeiss LSM 880 using a C-Apochromat 40x Water NA 1.2 objective lens. Cells were pretreated with 
dantrolene 100 nM or sitagliptin 200 nM then exposed to the cocktail of cytokines (IL1-β 50 ng/mL, IFN-y 50 ng/
mL). The cell permeable calcium sensor Fluo-4 AM (Invitrogen) was then added at a concentration of 4 µM 
in 1 ml of RPMI or PBS for 15–20 minutes. Cells were washed to remove excess Fluo-4AM and drugs prior to 
imaging. Experiments were performed in 37 °C RPMI or 37 °C calcium-free DPBS. The incubator stage provided 
the physiological conditions of 37 °C and 5% CO2. Images were acquired as a time series of 2 minutes for each 
condition before and after the addition of 5 mM caffeine. Since Fluo-4 AM is a single-wavelength calcium sensor, 
the data shown are related to the variation of fluorescence intensity of the stimulated cells (ΔF) relative to the 
basal condition (F0). Signals from more than 50 cells were averaged for each condition to avoid differences due 
to different Fluo-4 concentrations in the cells. Photostability experiments were performed prior to each imaging 
session to verify the best acquisition conditions to give minimal photobleaching. Data analysis and simple image 
processing were carried out with ImageJ.
Measurement of glucose mediated insulin secretion. INS-1E cells or human islets were treated with 
dantrolene and sitagliptin for 24 hours. In addition dantrolene and sitagliptin were kept in KRB buffer during 
GSIS. INS-1E cells were incubated in KRB buffer with 0 mM glucose for 40 minutes at 37 degrees. Cells were then 
incubated with KRB buffer and 2.8 mM glucose for 1 hour followed by KRB with 16.7 mM glucose for 1 hour at 
37 degrees. Supernatant was collected for insulin quantification at the end of each incubation. Insulin levels were 
quantified using the Rat/Mouse insulin ELISA kit from EMD Millipore. Cells were lysed at the end of the exper-
iment and protein was quantified using a NanoDrop system from Thermo Scientific. Data was presented as total 
insulin level normalized to total protein.
Human islets from 3 different donors were hand picked and 8–10 islets were transferred to an eppendorf 
tube. Islets were incubated in KRB buffer with 3.3 mM glucose for 40 minutes. Islets were then exposed to either 
3.3 mM glucose or 16.7 mM glucose KRB buffer and after one hour buffer was collected for insulin analysis. 
Insulin levels were measured using the Stellux human insulin ELISA kit from ALPCO. DNA was extracted from 
islets using the Qiagen DNeasy Blood and Tissue Kit per protocol. DNA was quantified using a NanoDrop system 
from Thermo Scientific. Data was presented as total insulin level normalized to total DNA.
Statistics. All results are shown as mean ± SEM. Two-tailed Student’s t-tests were used to compare two treat-
ments. One-way ANOVA was performed using Graph Pad Prism software 6.0 for multiple comparisons. Levels 
of statistical significance were indicated as follows; *p < 0.05 compared to control and #p < 0.05 compared to 
cytokines or thapsigargin treated cells.
Figure 8. Cytokines Lead to Altered Cellular Calcium Homeostasis, and Induction of Βeta Cell Death. In beta 
cells cytokines cause increased ER stress, depletion of ER calcium, prevention of functional ER calcium release 
and elevation of cytosolic free calcium levels. This chain of events ultimately culminates in cell death. This study 
has proved that drugs targeting modulation of ER and cytosolic free calcium levels can prevent the activation of 
cytokine and ER stresses mediated pro-apoptotic pathways and decrease beta cell death.
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